Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
1. An anti-VEGF antibody or an antigen-binding fragment thereof comprising
a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 110, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 137, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 145, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 151.
2. The anti-VEGF antibody or an anti-VEGF antigen-binding fragment of claim 1 , wherein the anti-VEGF antibody or the anti-VEGF antigen-binding fragment comprises
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 167.
3. The anti-VEGF antibody or an antigen-binding fragment thereof of claim 1 , which is an anti-VEGF scFv comprising SEQ ID NO: 175.
4. A pharmaceutical composition comprising the anti-VEGF antibody or an antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.
5. A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of the anti-VEGF antibody or the antigen-binding fragment thereof of claim 1 to the subject to inhibit cancer cell growth, thereby treating the cancer.
6. The anti-VEGF antibody or an antigen-binding fragment thereof of claim 1 , which is an scFv, (scFv)2, scFvFc, Fab, or Fab′.
7. An anti-c-Met/anti-VEGF bispecific antibody comprising an anti-c-Met antibody that comprises two heavy chains and two light chains and an scFv of the anti-VEGF antibody linked to the C-terminus of each anti-c-Met antibody heavy chain, wherein the anti-c-Met heavy chain comprises
a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;
the anti-c-Met light chain comprises a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 10, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 11, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 13;
and the anti-VEGF scFv comprises a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 110, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 121, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 137, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 145, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 151.
8. The anti-c-Met/anti-VEGF bispecific antibody of claim 7 , wherein the anti-c-Met heavy chain comprises
SEQ ID NO: 17, and
the anti-c-Met light chain comprises SEQ ID NO: 18.
9. An anti-c-Met/anti-VEGF bispecific antibody of claim 7 , wherein the anti-c-Met heavy chain comprises
SEQ ID NO: 62, the 18 th to 462 nd positions of SEQ ID NO: 62, SEQ ID NO: 64, the 18 th to 461 st positions of SEQ ID NO: 64, SEQ ID NO: 66, or the 18 th to 460 th positions of SEQ ID NO: 66; and
the anti-c-Met light chain comprises SEQ ID NO: 68, the 21 st to 240 th positions of SEQ ID NO: 68, SEQ ID NO: 70, or the 21 st to 240 th positions of SEQ ID NO: 70.
10. A pharmaceutical composition comprising the anti-c-Met/anti-VEGF bispecific antibody of claim 7 , and a pharmaceutically acceptable carrier.
11. A method of treating a cancer in a subject, comprising administering a therapeutically effective amount of-the anti-c-Met/anti-VEGF bispecific antibody of claim 7 to the subject to inhibit cancer cell growth, thereby treating the cancer.
12. The anti-c-Met/anti-VEGF bispecific antibody of claim 7 , wherein the anti-VEGF scFv comprises SEQ ID NO: 175.